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Left ventricular assist device (LVAD) therapy has been proven to relieve heart
failure symptoms and improve survival, but is not devoid of bleeding and/or
thrombotic complications. Risk stratification tools have been utilized in other
cardiovascular disease populations to estimate the risk of bleeding and thrombosis
with and without anticoagulation, including the HAS-BLED, HEMORR2HAGES,
CHADS2 and CHA2DS2-VASc models. The study objective was to evaluate the
predictive value of available risk models for bleeding and thrombotic complications
in patients with an LVAD within one year of implantation.

Methods
This was a retrospective, single-center analysis of patients implanted with the
HeartMate II continuous-flow LVAD from July 2011 to June 2016. All patients who
received an LVAD within the study period were eligible for inclusion. The primary
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endpoint was the first occurrence of bleeding or thrombosis within one year from
implantation. Baseline risk model scores were calculated at the time of LVAD
implantation. Chi-square and student’s t-test were used to measure baseline
differences and compare mean risk model scores between patients who had an
event. A receiver operator characteristic (ROC) curve analysis was performed to
evaluate the accuracy of the risk models to predict an event.
Results
A total of 129 patients underwent LVAD implantation within the study time period.
Mean CHADS2, CHA2DS2-VASc, and HAS-BLED scores were not significantly
different in patients with and without an event. The mean HEMORR2HAGES score
was 3.09 and 2.51 in those with and without a bleeding event, respectively (p =
0.008). The ROC curve area for the HEMORR2HAGES model was the highest at
0.620.
Conclusions
The HAS-BLED, HEMORR2HAGES, CHADS2and CHA2DS2-VASc risk
stratification models did not accurately predict bleeding or thrombosis events in our
population. The mean HEMORR2HAGES model score was higher in patients who
experienced a bleeding event. However, this model did not have strong positive
predictive value. Better risk models are needed to predict bleeding and thrombotic
events in this patient population.

Keywords: left ventricular assist device, gastrointenstinal bleed, thrombosis,
HAS-BLED, HEMORR2HAGES, CHADS2and CHA2DS2-VASc

Introduction
Mechanical circulatory support (MCS) continues to be an essential management
strategy for patients with acute or chronic cardiac or pulmonary failure. In patients
with advanced heart failure (HF), the implantable left ventricular assist device
(LVAD) significantly reduces mortality compared to medical therapy in patients
awaiting transplantation (bridge-to-transplant) and those deemed ineligible
(destination therapy) (1). According to the Eighth Annual INTERMACS report,
there were 22,866 patients implanted with an FDA-approved MCS device from
June 2006 to December 2016 (2). Although LVAD therapy has been proven to
relieve HF symptoms and improve survival (1), the implantation of an LVAD
increases a patient’s risk for bleeding and/or thrombotic events (3,4). Conversely,
there are a reported 7810 bleeding events per 100 patient-months within the first
three months of implantation (2). Arterial non-central nervous system thrombosis,
venous thrombosis, and stroke have been reported as 162, 663, and 1162 events
per 100 patient-months within the first three months of LVAD implantation,
respectively (2). Unfortunately, there are no validated methods to aid in predicting
patients at a higher risk for such events.
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Risk stratification tools have been utilized in other cardiovascular disease
populations to estimate the risk of bleeding and thrombosis with and without
anticoagulation, including the HAS-BLED, HEMORR2HAGES, CHADS2, and
CHA2DS2-VASc models (5-8). In an effort to limit the devastating complications
following LVAD implantation, the previously validated risk models were recently
evaluated in LVAD patients. Koene, et al evaluated the HAS-BLED and CHA2DS2VASc models with outcomes to determine their predictive abilities. The results
demonstrated that both models were associated with greater risks of bleeding and
thrombotic events, respectively (9). In a later study by Kemal, et al, there was a
significant association between elevated HAS-BLED scores and bleeding
outcomes, but there was not an association between the CHA2DS2-VASc model
and thrombotic outcomes (10). Due to these conflicting results and the limited data
in this area, further investigation is warranted to better define methods for
predicting complications in these high-risk patients. Additionally, the CHADS2 and
HEMORR2HAGES risk stratification tools have not been studied in the LVAD
population. The aim of this study was to investigate the predictive value of the
HAS-BLED, HEMORR2HAGES, CHADS2, and CHA2DS2-VASc predictive models
for bleeding or thrombotic complications in patients with LVADs.

Methods
This was an IRB-approved, retrospective, single-center analysis of patients
implanted with a continuous-flow LVAD (CF-LVAD) from July 1, 2011 to June 30,
2016. All patients who received an LVAD in this timeframe were eligible for
inclusion. Exclusion criteria were defined as patients with a known clotting
disorder, less than 18 years of age, pregnancy, and prisoners. The primary
endpoint was the incidence of bleeding and/or thrombosis events up to one year
after implantation. Baseline risk model scores were calculated utilizing the
previously described HAS-BLED, HEMORR2HAGES, CHADS2, and CHA2DS2VASc models at time of implantation (5-8). Bleeding events included
gastrointestinal (GI) bleeding, intracranial bleeding, and other non-surgical
bleeding. Perioperative bleeding (any bleeding occurring within 48 hours of
implantation) was not defined as an event. Targeted chart review for bleeding
events was conducted on the basis of the thrombolysis in myocardial infarction
(TIMI) criteria for minor bleeding (hemoglobin drop ≥ 3 g/dL) during admission
and/or the administration of medications for urgent reversal of bleeding (factor
VIIa, four factor prothrombin complex concentrate, vitamin K, desmopressin,
octreotide, proton pump inhibitor continuous infusions, and/or danazol) based on
medication administration records (11). Thrombosis events were defined based on
the development of pump thrombosis, ischemic stroke, and/or systemic emboli.
Chart review for thrombotic events was performed using medication administration
records for alteplase and based on laboratory abnormalities suggestive of pump
thrombosis, including lactate dehydrogenase (LDH) ≥ 3x upper limit of normal and
plasma free hemoglobin (pfHgb) ≥ 40 g/dL (12). All bleeding and thrombotic events
were confirmed utilizing radiographic evidence, laboratory markers, medication
administration records, daily progress notes, and discharge summaries. All
patients were censored at time of first event, transplantation, death, or at one year
post-implantation. Patients were initiated and maintained on institution-specific
antithrombotic therapy at time of discharge, including warfarin and an antiplatelet
in many circumstances.
The VAD Journal: Predicting Bleeding and Thrombosis Complications in LVADs

Page 3 of 10

The VAD Journal: The journal of mechanical assisted circulation and heart failure

A student’s t-test was used to compare mean risk model scores between patients
with and without an event. A receiver operator characteristic (ROC) curve analysis
was performed to evaluate the accuracy of the risk models to predict an event.

Results
A total of 125 patients met inclusion criteria from July 1, 2011 to June 30, 2016.
The median age at time of implantation was 54 years (range 18 - 81 years). The
mean and median HAS-BLED, HEMORR2HAGES, CHADS2, and CHA2DS2-VASc
model scores are presented in Table 1. The majority of patients were Caucasian
(90.4%) and male (81.6%). Of 125 patients, 34 patients (27.2%) experienced a
bleeding event and 19 patients (15.2%) experienced a thrombotic event. Of the 34
patients with bleeding events, the following events were reported: GI bleed (n =
22), hematuria (n = 3), intracranial hemorrhage (n = 8), or other bleed (n = 6), with
five patients experiencing bleeding at two different sites. Thrombotic events
included pump thrombosis (n = 9), deep vein thrombosis/pulmonary embolism (n =
4), ischemic stroke (n = 4), or other (n = 2). Seven of the bleeding and thrombosis
events that occurred were associated with admission to the hospital and ultimately
contributed to inpatient mortality. Median time to bleeding event was 93 days;
median time to thrombotic event was 67 days.

Table 1. Baseline Characteristics
Baseline Characteristics (n = 125)
Variable

Number of Patients

Male
Caucasian
Median Age at Implantation (years)
Hypertension
Heart Failure
Diabetes
Prior History of Stroke or Transient Ischemic Attack
Vascular Disease
Renal Disease
Liver Disease
Alcohol Use
History of Malignancy
Antiplatelet Use
History of Bleed
Baseline Anemia

Risk Stratification Tool
HAS-BLED
HEMORR2HAGES
CHADS2
CHA2DS2-VASc
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102 (81.6%)
113 (90.4%)
54
102 (81.6%)
125 (100%)
60 (48%)
8 (6.4%)
73 (58.4%)
32 (25.6%)
6 (4.8%)
6 (4.8%)
11 (8.8%)
104 (83.2%)
5 (4%)
52 (41.6%)

Mean
(Stdev)

Median (Range)

2.26 (0.99)
2.66 (1.11)
2.47 (0.87)
3.39 (1.24)

2 (0 – 5)
3 (0 – 6)
2 (1 – 5)
3 (1 – 6)
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Table 2. Bleeding scores and bleeding events
Primary Outcomes

HAS-BLED
HEMORR2HAGES
CHADS2
CHA2DS2-VASc

HAS-BLED
HEMORR2HAGES
CHADS2
CHA2DS2-VASc

No Bleeding Event
n = 91 (stdev)

Bleeding Event
n = 34 (stdev)

P - Value

2.14 (0.93)
2.51 (0.11)
2.47 (0.87)
3.32 (1.24)

2.56 (0.19)
3.09 (0.20)
2.47 (0.86)
3.59 (1.26)

0.056
0.008
0.991
0.283

No Thrombotic
Event
n = 106 (stdev)

Thrombotic
Event
n = 19 (stdev)

P - Value

2.25 (1.00)
2.66 (1.07)
2.46 (0.84)
3.40 (1.25)

2.26 (0.99)
2.68 (1.34)
2.53 (1.02)
3.37 (1.26)

0.973
0.932
0.768
0.929

The mean HEMORR2HAGES score was higher in patients who suffered a bleeding
event at 3.09 vs patients who did not at 2.51 (p = 0.008). However, there was no
statistically significant difference in mean HAS-BLED scores: 2.14 vs 2.56 (p =
0.056) (Table 2). ROC for the HAS-BLED and HEMORR2HAGES risk models
showed a weak correlation between scores and bleeding outcomes (Figure 1).

A

B

Figure 1: (A) HAS-BLED ROC curve with area under curve (AUC) of 0.603,
standard error 0.059, and asymptotic significance value of 0.076. (B)
HEMORR2HAGES ROC curve with AUC of 0.620, standard error 0.054, and
asymptotic significance value of 0.028. For both graphs, there is little correlation
between risk stratification tool and bleeding events seen.
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The mean CHADS2 and CHA2DS2-VASc scores were not statistically significantly
different for patients who had a thrombotic complication (Table 2). ROC curves
were similarly not correlated with thrombotic complications (Figure 2).

A

B

Figure 2: (A) CHADS2 ROC with AUC of 0.548, standard error 0.071, and
asymptotic significance value of 0.482. (B) CHA2DS2-VASc ROC with AUC of
0.513, standard error 0.065, and asymptotic significance value of 0.843. For both
graphs, there is no relationship seen between increasing scores and thrombotic
events.

Discussion
In our study population, 42.4% of all patients suffered either a bleeding or
thrombotic complication within the first year following LVAD implantation. Despite
the high incidence of events in this population, the HEMORR2HAGES score was
the only risk stratification tool to find a statistically significant difference between
patients who did and did not suffer a bleeding event. However, further ROC curve
analysis did not show strong correlation with higher scores, suggesting that the
HEMORR2HAGES score does not provide an accurate estimation of patients who
are likely to suffer a bleeding event. This finding also highlights the complex
pathophysiology of bleeding events in this population and the need for further
identification of risk factors contributing to bleed outside of the risk stratification
tools analyzed in this study.
Despite substantial improvements in the management of HF with CF-LVADs,
complications with potentially devastating sequelae remain prevalent. An important
next step in LVAD therapy would be to limit the number of these complications or
to establish a better modality to predict and prevent adverse events in at-risk
patients. However, the mechanism of increased bleed risk is proposed to be
multifactorial, making it challenging to implement a one approach to limit bleeding
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complications. Specifically, the mechanical shear stress induced by the LVAD may
lead to uncoiling of von Willebrand multimers, resulting in increased proteolysis by
ADAMTS13 and subsequent development of acquired von Willebrand disease.
Additionally, the non-pulsatile nature of CF-LVADs may lead to the development of
angiodysplasia and arteriovenous malformations (AVMs). The development of
AVMs is particularly common within the GI tract as a result of decreased pulse
pressure. Similar to the pathophysiology of bleeding, several mechanisms of
thrombosis have been hypothesized including: inorganic material exposure leading
to clotting cascade activation, the mechanical shear stress of the device leading to
platelet damage and hemolysis/inflammation, and various pump-related risk
factors (continuous-flow vs pulsatile flow; centrifugal vs axial) (13-15).
In the MOMENTUM 3 trial, the HeartMateTM 3 centrifugal-flow device (Abbott) was
associated with greater event-free survival (alive and free from disabling stroke
and emergent pump replacement due to complications) (76.9%) as compared to
the HeartMate II axial-flow device (Abbott) (64.8%) at 2 years (P < 0.001) (15).
Pump thrombosis, stroke, and bleeding complications were also lower in the
HeartMate 3 cohort, reinforcing the importance of pump-related factors in
coagulopathy and thrombosis risk (15). These numerous factors complicate the
determination of risk for each patient, since patients may have differing
hematologic responses to the implantation of an LVAD. Despite these differences,
many institutions have adopted a standard approach to implementing
antithrombotic therapy, often including the use of antiplatelet therapy (aspirin 81325 mg/day) and warfarin with variable patient-specific international normalized
ration (INR) goals. Beyond the mechanistic factors that the LVAD contributes,
antithrombotic therapy further complicates the hemostatic picture, creating a
difficult balance between bleeding and thrombotic events for these patients.
The incidence of bleeding and thrombotic events in this study (27.2% and 15.2%)
was similar to the studies by Koene (24.9% and 12.7%) and Kemal (22.1% and
15.2%) (9, 10). Though both studies examined baseline risk stratification tool
scores prior to LVAD implantation, the previous finding that HAS-BLED and
CHA2DS2-VASc correlates with bleeding and thrombotic outcomes was not
replicated in our study population. There are several notable differences that may
contribute to the conflicting results among the evaluated studies. In the study by
Koene, et al, no patients were documented as having hypertension in the HASBLED risk tool compared to 81.6% in the present study. Additionally, while labile
INR was included in the study by Koene, et al, only 24.9% of the patient population
had INR data available. The current study did not incorporate labile INR into
baseline calculations due to inconsistent documentation and the controversy in the
best method for calculating time in therapeutic range. There are limitations to
excluding labile INR history, since the HAS-BLED score initially included this for
prediction of bleeding events up to one year (7). However, withholding the
incorporation of pre-implantation labile INRs minimizes the assumption that
patients will continue to have labile INRs post-implantation. Drawing further
comparisons to previous investigations, the study by Kemal and colleagues
included mostly patients implanted with the HeartWare® device (HVAD,
Medtronic) and only 21.5% with the HeartMate II device (10). As discussed
previously, the device plays a significant role in the etiology of bleeding and
clotting in these patients, and differences in device type and function may change
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the likelihood of either event occurring. These two different devices did not have
significantly different number of thromboembolic events, but nearly all of the
bleeding events occurred in the HVAD group (30 of 32 events), meaning that the
finding that HAS-BLED scores predicted outcomes in this study was mostly driven
by patients with HVAD. As a result of study heterogeneity and differences in
institutional practices, it is difficult to derive conclusions regarding the use of these
risk stratification tools for all patients receiving a CF-LVAD and highlights the
difficulty in achieving strong external validity in this patient population.
Despite the findings in the study by Koene, et al, there remains little investigation
into the application of risk stratification tools and prospective interventions into
antiplatelet/anticoagulant management. Most modifications to a patient’s regimen
occur secondary to an identified event and/or history of hemorrhagic or
thromboembolic events. Knowing the significant morbidity, mortality, and cost of
treating these complications, there remains a large unmet need for better
predictive models to limit these adverse events. Koene and colleagues stratified
patients into high (≥ 3) and low risk (< 3), suggesting that this can be an approach
to assigning patients to different management strategies. However, the results of
their study have not been consistently replicated, and there have not been
prospective trials evaluating this method. In a more recent study, a predictive
model for the risk of GI bleed was created from retrospective outcomes data up to
3 years after LVAD implantation. This model incorporated age > 54 years, history
of previous bleed, coronary artery disease, chronic kidney disease, severe right
ventricular dysfunction, mean pulmonary arterial pressure (MPAP) < 18 mmHg,
and glucose > 107 mg/dL. Patients assigned into low risk (0-1 points), intermediate
risk (2-4 points), and high risk (5-9 points) had 3-year GI bleed risks of 4.8%,
39.8%, and 83.8%, respectively [16]. While still lacking prospective confirmation of
these results, this tool may better identify a patient’s risk for GI bleed, specifically.
However, this study did not propose specific interventions to reduce the risk of
bleed and did not assess thrombotic complications, which must be carefully
balanced before using this algorithm to modify antithrombotic therapy.
A limitation of this study includes its retrospective nature, as our study was
restricted to documentation obtained from the electronic health record. Also, as
previously discussed, labile INR was not represented in this study and warrants
further investigation in the use of various time-in-therapeutic range calculators and
outcomes specifically for patients with LVADs. The role of continuously
reassessing risk, and at which frequency to do so remains unclear, as all
approaches have assessed a baseline risk stratification tool score to predict future
outcomes. Because this retrospective analysis occurred in a single institution with
a single type of LVAD, the external validity must be interpreted with caution.
However, the inconsistent results compared to previous single-center studies
highlights the need for large, multi-center studies to evaluate risk factors for
developing bleeding and thrombotic events, which may be achieved through the
INTERMACS database and collaboration between multiple institutions to achieve
better outcomes in these patients. Additionally, the collaboration between multiple
centers may allow for the identification of a certain incidence of hemorrhagic and
thromboembolic complications that is deemed ‘actionable’ to modify the patient’s
antithrombotic regimen post-implantation. A common approach to modify a
patient’s regimen may be to decrease or increase a patient’s INR range for
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warfarin management, but the specific modification based on an ‘actionable’ level
of risk of bleeding or clotting still requires further investigation.

Conclusion
Current commonly used risk stratification tools lack consistency in accurately
predicting bleeding and thrombotic complications in patients with CF-LVADs. The
inconsistency in results between centers suggest that a larger, multi-center study
is necessary to confirm these findings. Additionally, further analysis into individual
risk factors and development of a unique scoring system may provide helpful
information into the initial management of patients being implanted with an LVAD,
allowing for a decrease in complication rates due to bleeding and thrombosis.
However, further work is warranted to identify specific patients that require
modification of antithrombotic therapy and the specific modifications that are
needed.
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